NCT01587040 - Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 20, 2012

Primary Completion Date

May 23, 2018

Study Completion Date

May 23, 2018

Conditions

Neoplasm Malignant

Interventions

DRUG

SAR245408

Pharmaceutical form: capsule or tablet Route of administration: oral

DRUG

SAR245409

Pharmaceutical form: capsule or tablet Route of administration: oral

Trial Locations (21)

3000

Investigational Site Number 056001, Leuven

19111

Investigational Site Number 840017, Philadelphia

26506

Investigational Site Number 840018, Morgantown

30912

Investigational Site Number 840006, Augusta

33919

Investigational Site Number 840104, Fort Myers

34295

Investigational Site Number 250004, Montpellier

35205

Investigational Site Number 840010, Birmingham

37232

Investigational Site Number 840007, Nashville

43210

Investigational Site Number 840015, Columbus

44718

Investigational Site Number 840020, Canton

63110

Investigational Site Number 840021, St Louis

69495

Investigational Site Number 250003, Pierre-Bénite

75230

Investigational Site Number 840003, Dallas

76038

Investigational Site Number 250005, Rouen

78229

Investigational Site Number 840005, San Antonio

80262

Investigational Site Number 840022, Denver

90024

Investigational Site Number 840009, Los Angeles

90033

Investigational Site Number 840008, Los Angeles

02115

Investigational Site Number 840004, Boston

08903

Investigational Site Number 840002, New Brunswick

08035

Investigational Site Number 724001, Barcelona